Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H23ClN2O8.ClH |
| Molecular Weight | 515.341 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C(Cl)=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
InChI
InChIKey=CBHYYLPALVVVEY-MRFRVZCGSA-N
InChI=1S/C22H23ClN2O8.ClH/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21;/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31);1H/t7-,8-,15-,21-,22-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C22H23ClN2O8 |
| Molecular Weight | 478.88 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17638695 | https://www.ncbi.nlm.nih.gov/pubmed/6404649
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17638695 | https://www.ncbi.nlm.nih.gov/pubmed/6404649
Chlortetracycline (trade name Aureomycin, Lederle) is a tetracycline antibiotic, the first tetracycline to be identified. It was discovered in 1945 by Benjamin Minge Duggar working at Lederle Laboratories under the supervision of Yellapragada Subbarow. Duggar identified the antibiotic as the product of an actinomycete he cultured from a soil sample collected from Sanborn Field at the University of Missouri. The organism was named Streptomyces aureofaciens and the isolated drug, Aureomycin, because of their golden color. Chlortetracycline inhibits cell growth by inhibiting translation. It binds to the 16S part of the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. In veterinary medicine, chlortetracycline is commonly used to treat conjunctivitis in cats.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006412 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6404649 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Aureomycin Approved UseUnknown |
|||
| Curative | Aureomycin Approved UseUnknown |
|||
| Curative | Aureomycin Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1560.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32988509/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORTETRACYCLINE plasma | Gallus gallus domesticus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13415.51 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32988509/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORTETRACYCLINE plasma | Gallus gallus domesticus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32988509/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORTETRACYCLINE plasma | Gallus gallus domesticus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
50% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32988509/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CHLORTETRACYCLINE plasma | Gallus gallus domesticus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/aureomycin.html
Cattle: 0.1-10 mg per lb body wt per day; Swine: 10 mg per lb body wt per day; Turkeys: 25 mg per lb body wt per day;
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17638695
Chlortetracycline activity was determined against 37 Mycoplasma putrefaciens isolates. Chlortetracycline was tested at concentrations ranged from 4 to 0.03 mg/ml/ The MIC was defined as the lowest concentration in which there was no bacterial growth, as evidenced by a lack of pH color change at the time the drug-free growth control showed a color change. This change of color was evident after 24 h of incubation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:55 GMT 2025
by
admin
on
Mon Mar 31 17:46:55 GMT 2025
|
| Record UNII |
O1GX33ON8R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01258MIG
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
DTXSID2045076
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
O1GX33ON8R
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
42545
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | RxNorm | ||
|
m3468
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
Chlortetracycline hydrochloride
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
222-936-0
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
CHLORTETRACYCLINE HYDROCHLORIDE
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | Description: Yellow crystals or a yellow, crystalline powder; odourless.Solubility: Soluble in about 100 parts of water and in about 250 parts of ethanol (~750 g/l) TS; practically insoluble in acetone Rand ether R.Category: Antiinfective drug.Storage: Chlortetracycline hydrochloride should be kept in a tightly closed container, protected from light. | ||
|
200-591-7
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
O1GX33ON8R
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
1129007
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
C47448
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
54682468
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
13252
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
3671-08-7
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
CHEMBL404520
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
64-72-2
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
DBSALT001148
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY | |||
|
100000084806
Created by
admin on Mon Mar 31 17:46:55 GMT 2025 , Edited by admin on Mon Mar 31 17:46:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
sum of the contents of chlortetracycline hydrochloride and tetracycline hydrochloride : 94.5 per cent to 102.0 per cent (anhydrous substance)
ASSAY (HPLC)
EP
|
||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|